GlassScriptPhysician profile
Charnjeet Sandhu
NPI 1669904256
$9,241.53
in general payments reported to CMS, 2019-2025
19 companies · $7,326 in 2025
The $7,326 reported for 2025 was more than what 87% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.52 · 2022: $555 · 2023: $733 · 2024: $533 · 2025: $7,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $5,500 · Food and Beverage: $2,130 · Travel and Lodging: $960 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $5,500.00 |
| Food and Beverage | $2,130.49 |
| Travel and Lodging | $960.35 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $5,599.18 | 2025 | Auryon Laser System 100-120 Vac, Angiovac |
| Medtronic, INC. | $751.71 | 2023-2025 | Venaseal, Onyx Frontier, Corevalve Evolut R |
| Philips North America LLC | $581.27 | 2025 | Coronary Undivided, Coronary Other |
| Boston Scientific Corporation | $386.53 | 2023 | Opticross |
| Abbott Laboratories | $345.26 | 2022-2025 | Jot Dx, Amplatzer Talisman |
| Edwards Lifesciences Corporation | $306.73 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $302.57 | 2021-2023 | |
| Abiomed | $216.56 | 2022-2023 | Impella |
| Heartflow, INC. | $169.16 | 2025 | |
| Getinge USA Sales, LLC | $140.41 | 2025 | Cardiosave Rescue |
| E.R. Squibb & Sons, L.L.C. | $110.10 | 2022-2023 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.26 | 2021-2022 | |
| Penumbra, INC. | $80.07 | 2025 | Indigo System |
| Amgen INC. | $44.42 | 2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $36.36 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $21.36 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $18.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.01 | 2025 | Jardiance |
| Terumo Medical Corporation | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charnjeet Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.